Is it true that … natural beauty products are always gentler on skin?
For starters, not everything labelled 'natural' is entirely sourced from nature. 'I came across a crude study that looked at 100 skincare products on Amazon marketed as natural. Only 42% truly were,' Simpson adds. In fact, most 'natural' skincare products contained at least two synthetic ingredients.
Beyond this, just because something is sourced from natural ingredients doesn't mean it's gentle on every skin type. Though plant-based, ingredients including fragrances and essential oils such as cinnamon, tea tree, peppermint and linalool can cause irritation for some people. Lanolin, a moisturising agent derived from sheep's wool, is another common allergen.
Sign up to Inside Saturday
The only way to get a look behind the scenes of the Saturday magazine. Sign up to get the inside story from our top writers as well as all the must-read articles and columns, delivered to your inbox every weekend.
after newsletter promotion
Some synthetic ingredients, such as certain scents and colourings, can be just as irritating, but that isn't always the case. 'Some are scientifically developed to be more gentle on the skin and to have a reduced chance of causing potential reactions,' says Simpson.
Her bottom line? Not all natural products are 'good', and not all synthetic ones are 'bad'. It's about finding what works for you. 'Go with what your skin tolerates and what fits your budget.'
If you have sensitive skin, she recommends looking for products with the lowest number of ingredients. And if you suspect you have had a reaction to a product – even months after you started using it – it's always smart to take a break so you can see whether it is to blame.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Powys County Times
26 minutes ago
- Powys County Times
Government partners with Mounjaro maker to tackle obesity
The Government has joined forces with the pharmaceutical giant that makes weight loss jab Mounjaro in a bid to tackle obesity. The move could see patients accessing care at pharmacies or by using online platforms. The £85 million programme from Eli Lilly and the Department for Science, Innovation and Technology (DSIT) has been designed to look at how obese patients can access weight management care more easily. This includes through community services, in pharmacies and online. Using these tools, eligible patients could be treated 'in a matter of months', according to Health Secretary Wes Streeting. Under the agreement, the Government will contribute up to £50 million in UK-wide investment. Meanwhile, Eli Lilly will back the programme with £35 million, and NHS organisations will be able to apply for a share of the funding. Successful applicants can then use the cash to run and assess a pilot to build evidence for efficient obesity care in the UK. Eligible patients could be able to access these innovative services by summer 2026, the Government said. Mr Streeting warned that obesity is one of the leading causes of ill health and costs the health service billions. 'Yet, we now have the science, technology and knowledge to help tackle the obesity epidemic, if we seize this opportunity,' he added. 'This collaboration will help patients living with obesity in a matter of months – through testing better access to weight loss services and treatments. 'In the long-term it will inform how we can better tackle one of the biggest modern day health challenges and, through our Plan for Change, create an NHS that is fit for the future.' Science and Technology Secretary Peter Kyle said new ways of accessing support 'could be transformational for people's quality of life, and for society'. They could free obese people from 'ill-health that holds them back in daily life – while reducing the strain on our NHS', he added. NHS England national medical director Dr Claire Fuller said: 'Obesity is one of the biggest public health challenges we face and costs the NHS billions of pounds every year, so this collaboration between government and industry to drive new ways of supporting people with obesity could make a huge difference. 'The NHS is already developing and rolling out a range of ways to help people to manage their weight and live healthier lives, with patients benefiting from wraparound care from local weight management teams and via online support services, but we are excited by the potential of this collaboration to accelerate efforts to tackle obesity as the NHS moves from treatment to prevention as part of the 10-Year Health Plan.' Professor Rachel Batterham, senior vice president for international medical affairs at Lilly said: 'The launch of this programme marks an important milestone in advancing new models of care for obesity.' Henry Gregg, chief executive of the National Pharmacy Association, welcomed the announcement but warned that funding should cover costs for pharmacies. 'This is a vital step forward in addressing one of the most pressing health challenges facing our country,' he said. 'It's important that any funding made available is sufficient to cover the costs involved for pharmacies to provide wraparound care and support. 'Community pharmacies already support over 1.4 million people every month with weight management services delivered by pharmacists who are highly trained professionals providing expert, accessible care. 'Despite this, the current NHS rollout remains extremely limited, with only a small number of eligible patients receiving support for obesity with weight loss treatments, and it is vital that this changes. 'With the right funding, pharmacies can scale up delivery quickly – ensuring more people get the help they need, when and where they need it.' News of the programme comes after Lilly published the results of a trial assessing a new daily pill for weight loss, which could offer a new and convenient alternative to jabs. People taking orforglipron lost an average of 12.3 kilograms in 72 weeks compared with those not taking the drug. The phased NHS roll-out of Lilly's weight loss jab Mounjaro to patients in England started in June for patients with a body mass index (BMI) over 40 and at least four co-morbidities.
Telegraph
27 minutes ago
- Telegraph
Students fast tracked for autism diagnosis while children wait years
University students will be fast-tracked for autism diagnosis while children continue to wait years, The Telegraph can reveal. Students will be taken out of the regular local services amid surging referrals for young people, according to a trial at University College London starting in the upcoming academic year. Those still on the current waiting lists will still have to wait several years while students use the dedicated service. The NHS is providing £80,000 in funding to UCL, which is setting up a first-of-its-kind autism clinic to focus solely on students. The university-specific NHS clinic will investigate if the approach improves wait list times for both the general population as well as students during the course of the project from October 2025 until November 2026. Officials have said university students pose a 'specific challenge to the dynamics of adult waiting lists' because students can spend longer waiting for an appointment than the length of a degree. This serves to inflate waiting times for the general public in the neighbouring area as well as failing the student, officials say. There has been a 15-fold increase in the number of 18-24 year-olds seeking an appointment for an autism diagnosis since 2019, official data show. Demand for specialist clinics has soared since the Covid-19 pandemic as a result of increased awareness of autism symptoms, often driven by social media. The huge waiting lists mean people often wait several years to be seen by a clinician and get a diagnosis. This overburdening of autism services is forcing individuals with profound autism who require 24/7 care, including non verbal people, to suffer serious delays to their treatment with lifelong ramifications. In the contract between the NHS England and UCL, officials wrote: 'Removing student populations from local specialist autism teams could positively impact the waiting list.' A recent report found that almost a third of self-harm and suicide cases among university students involve neurodiverse individuals, including those with ADHD and autism Autism waiting lists have ballooned in recent years for all ages but most noticeably in under-25s. Telegraph analysis reveals that there were more than a quarter of a million people awaiting an appointment for a diagnosis in March 2025, the most recent available data, up from 17,400 in April 2019. Almost 75,000 children under 10 are on the waiting list, up more than 12-fold in six years from less than 6,000. There are almost 91,000 people between 10 and 25 currently awaiting a referral, up 12-fold from 7,700 pre-pandemic. In contrast, there are just 735 over-65s on the waiting list. However, this is up more than 11-fold itself from just 65 in 2019. An NHS England spokesman told The Telegraph: 'Backed by NHS funding, University College London is trialling a first-of-its-kind dedicated autism clinic and assessment referral pathway for university students. 'The aim is to test whether separating students from the mainstream waiting list leads to faster diagnosis and better support during the often-challenging transition to higher education. 'The project will also identify ways to improve how autistic and neurodivergent students are supported during university, as well as looking for ways to improve NHS services for autistic people more generally.' The system will only be open to UCL students as part of the pilot programme. A UCL spokesman said: 'The project has a number of aims including to pilot and evaluate a referral pathway for UCL students, so that if they suspect they are autistic, they can get a timely assessment at UCL. 'Given current waiting lists in NHS adult services, some people needing autism assessment at university cannot get their assessment until after they graduate.' Other goals of the project are to improve support that can be offered to autistic students and also improve training to clinicians. The UCL spokesman added: 'It is intended that this research will generate a range of new ideas for improving the effectiveness and efficiency of autism services, that can be adopted in settings across the country, such as NHS autism assessment clinics and general mental health services. 'This has the potential to contribute to improvements in the quality of services and waiting times nationally.' 'Diagnosis can be lifesaving' Mel Merritt, the head of policy and campaigns at the National Autistic Society, said: 'This trial is an opportunity to provide faster diagnosis and better support for autistic university students. 'An autism diagnosis is often life changing and can be lifesaving. University is an important transitional time for many young autistic people and it's important they receive a timely diagnosis so they can get the right support. 'Nine in 10 people wait longer than the recommended 13 weeks and the average wait time is more than 14 months, with many waiting years. 'Without a diagnosis, avoidable crises can develop and, while it shouldn't be the case, often support isn't provided until someone has a diagnosis. At school, this means children and young people miss out on years of their education. 'The Government must provide urgent funding for diagnosis services across the country to end this worsening crisis, and make sure autistic people and their families get the support they need.'
The Sun
27 minutes ago
- The Sun
‘Anti-vax' mum accused of ‘sacrificing' daughter, 22, who died of ‘treatable cancer' claims she's victim of a witch hunt
A MUM accused by her son of 'sacrificing' his sister, who died from "treatable" cancer, has told an inquest she is the victim of a 'witch hunt'. Kay 'Kate' Shemirani is a former nurse, struck off in 2021 for spreading anti-medicine and anti-vaccine Covid-19 misinformation. 7 7 7 She has denied influencing her 23-year-old daughter Paloma Shemirani's decision to refuse treatment for non-Hodgkin lymphoma - a type of blood cancer which starts in the lymph nodes. Paloma was a University of Cambridge graduate and a Miss Universe Great Britain 2021 finalist. She collapsed on July 19 last year and died five days later of a heart attack. A few months earlier, doctors told Paloma, who was originally from Uckfield in East Sussex, her cancer was "treatable" and that she had an 80 per cent chance of recovery with chemotherapy. On Monday, the inquest in Maidstone heard Kate deny influencing her daughter's decision. She said: 'It doesn't matter what my view was, it was what Paloma wanted to do.' The BBC reported the court was played a voice note from Kate to Paloma's boyfriend, sent two or three days after the diagnosis at Maidstone Hospital in December 2023. In it, she told him to 'put Paloma in a wheelchair to take her down to the car' and to listen to the message 'in private and away from Paloma's ears'. She also told him to drive 'very carefully without braking sharply'. In response, Kate said she would need the 'forensic data' before agreeing the voice note heard by the court was from her, but added that whoever left the message gave 'fantastic advice'. Two signs of cancer that could be mistaken for cold weather symptoms - and when to see a GP She said she had not wanted Paloma to hear because she would have been frightened that she could be injured if her boyfriend drove too fast. When asked about her views on chemotherapy, Kate said: "Why is this about me and my opinions? Is it a witch hunt?" Paloma's twin brother, Gabriel, previously told the inquest that when Paloma was first diagnosed she was considering chemotherapy. That was 'before their parents started to pressure her against it', he added. "I blame my mother entirely for my sister's death", he said, by "obstructing" his sister from receiving treatment. "In short, I believe that she sacrificed Paloma's life for her own principles, I believe that she should be held accountable for Paloma's death," said Gabriel. He added: 'Paloma had a complicated relationship with our mother, maybe it is because she had a complicated relationship that she decided to rekindle that relationship when she became ill." 7 7 Kate told the inquest she had asked for Paloma to have all her medical notes and results so she could get all the facts and a second opinion from doctors they knew in Iran and Mexico. She said she did not know if the records were ever sent to another oncologist or haematologist for the second opinion 'because they were Paloma's records and she was 22 - an adult'. Alison Hewitt, counsel at the inquest, asked Kate: 'It is the case, isn't it, that you have expressed publicly views which are contrary to chemotherapy... you consider chemotherapy is a dangerous and toxic process and one that you wouldn't advise someone suffering cancer undergoes?' Kate branded the question 'slanderous' and 'not true', adding: 'In all my public appearances I say people should get all the information and then decide.' When pushed on whether she had described chemotherapy as mustard gas, she replied: 'This is not relevant. You're making slanderous accusations. People should be able to choose.' Kate has said she had a tumour removed through surgery. Online, however, she credits alternative therapies for her recovery and says she used a programme including juices and coffee enemas to become 'cancer-free'. The former nurse said she would have supported her daughter 'physically and financially' whatever her decision on receiving treatment. Earlier in the hearing, when describing the months before her daughter's death, Kate said Paloma had chosen treatment which included nutrition, juices and spiritual support, claiming that many of her symptoms had disappeared. Intensive care consultant Dr Peter Anderson told the court a scan showed a large mass in Paloma's chest and neck compressing her airways and affecting major blood vessels. Either could have caused the cardiac arrest, he added. The inquest continues. 7 Non-Hodgkin lymphoma treatment, as recommended by the NHS Non-Hodgkin lymphoma is usually treated with chemotherapy or radiotherapy, although some people may not need treatment straight away. In a few cases, if the initial cancer is very small and can be removed during a biopsy, no further treatment may be needed. If non-Hodgkin lymphoma is low grade (slow developing) and a person is well, a period of "watch and wait" is often recommended. This is because some people take many years to develop troublesome symptoms and starting treatment immediately is often felt to be unnecessary. But in other cases, chemotherapy is used to kill cancer cells. If non-Hodgkin lymphoma doesn't get better with initial treatment (known as refractory lymphoma), you may have a course of chemotherapy at a stronger dose. But this intensive chemotherapy destroys your bone marrow, and can lead to the following side effects: nausea and vomiting diarrhoea loss of appetite mouth ulcers tiredness skin rashes hair loss infertility, which may be temporary or permanent A stem cell or bone marrow transplant is then needed to replace the damaged bone marrow. Radiotherapy is most often used to treat early-stage non-Hodgkin lymphoma, where the cancer is only in one part of the body. And for some types of non-Hodgkin lymphoma, you may have a type of medicine called a monoclonal antibody. These medicines attach themselves to both healthy and cancerous cells, and signal to the immune system to attack and kill the cells. Other potential non-Hodgkin lymphoma treatments include: Cancer growth blockers Steroid medicine Immunotherapy Source: NHS
